Curis, Inc. (NASDAQ:CRIS)
Industry: Healthcare

OFF LIST - 1725 consecutive market days: OFF LIST as of 07/30/2009 Through 11/14/2016

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. The company has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.

Current Quote*
Last: $1.520
Change: -0.020
Book: $Unk
Volume: 149,614

As Of: 11/14 13:01 ET
*Quotes delayed by 20min.

Graphs for CRIS


3 Month Graph


6 Month Graph


1 Year Graph